Nystatin Pastille for the Prophylaxis of Oral Candidiasis in Patients With AIDS or AIDS Related Syndromes
Nystatin
Blood-Borne Infections+22
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 12 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria Concurrent Medication: Allowed: Experimental drugs (IND drugs) which are targeted specifically against the AIDS virus or which stimulate the immune system. Systemic or oral antibiotics. Patients must have AIDS or AIDS-related syndromes (HIV infection: Group III or IV, CDC classification) and not have been treated for oral candidiasis during the past year. Patients can be entered into the study who have: Other oral lesions due to Kaposi's sarcoma, herpes zoster, and herpes simplex. A positive or negative oral culture for Candida. Must be able to follow instructions regarding the use of a pastille. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Oral lesions diagnostic of oral candidiasis or systemic candidiasis. Suspected or proven candidal esophagitis. Patients with the following are excluded: Oral lesions diagnostic of oral candidiasis or systemic candidiasis. Receiving any effective antifungal agent orally or intravenously within 72 hours of study entry. Not expected to survive for at least 6 months. Unable to voluntarily maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. Known hypersensitivity to nystatin. Suspected or proven candidal esophagitis. Prior Medication: Excluded within 72 hours of study entry: Any oral or intravenous antifungal agent.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 2 locations
Birmingham Veterans Administration Med Ctr / Univ of Alabama
Birmingham, United StatesOpen Birmingham Veterans Administration Med Ctr / Univ of Alabama in Google MapsBristol - Myers Squibb Co
Princeton, United States